BRAF and neoplasm: However, the pre-clinical literature includes conflicting results, such as a study by Gunda et al. [107] that showed short (2–3 week) tumor control and re-establishment of an immune suppressive environment in ATC mice treated with combination BRAF and immune checkpoint blockade.